Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INMD Stock Forecast 2026-2027
$14.33
Current Price
$928.21M
Market Cap
Buy 1
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to INMD Price Targets
+46.5%
To High Target of $21.00
+11.7%
To Median Target of $16.00
+4.7%
To Low Target of $15.00
INMD Price Momentum
+5.9%
1 Week Change
+6.5%
1 Month Change
-4.0%
1 Year Change
-2.5%
Year-to-Date Change
-14.4%
From 52W High of $16.74
+12.7%
From 52W Low of $12.72
📊 TOP ANALYST CALLS
Did INMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Inmode is one of their latest high-conviction picks.
Latest INMD Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, INMD has a neutral consensus with a median price target of $16.00 (ranging from $15.00 to $21.00). The overall analyst rating is Buy (6.3/10). Currently trading at $14.33, the median forecast implies a 11.7% upside. This outlook is supported by 1 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Miksic at Barclays, projecting a 46.5% upside. Conversely, the most conservative target is provided by Caitlin Cronin at Canaccord Genuity, suggesting a 4.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INMD Analyst Ratings
1
Buy
5
Hold
0
Sell
INMD Price Target Range
Low
$15.00
Average
$16.00
High
$21.00
Current: $14.33
Latest INMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 17, 2025 | Canaccord Genuity | Caitlin Cronin | Hold | Maintains | $15.00 |
| Nov 6, 2025 | UBS | Danielle Antalffy | Neutral | Maintains | $16.00 |
| Oct 10, 2025 | Canaccord Genuity | Caitlin Cronin | Hold | Maintains | $16.00 |
| Oct 10, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Jul 30, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Jul 30, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $21.00 |
| Jul 11, 2025 | Canaccord Genuity | Caitlin Cronin | Hold | Maintains | $15.00 |
| Apr 30, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $24.00 |
| Apr 29, 2025 | BTIG | Sam Eiber | Neutral | Downgrade | $N/A |
| Apr 29, 2025 | UBS | Danielle Antalffy | Neutral | Maintains | $16.25 |
| Apr 29, 2025 | Canaccord Genuity | Caitlin Cronin | Hold | Maintains | $15.00 |
| Apr 28, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Apr 14, 2025 | Jefferies | Matthew Taylor | Hold | Maintains | $15.00 |
| Apr 14, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Apr 9, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Feb 5, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $29.00 |
| Feb 4, 2025 | Needham | Mike Matson | Hold | Maintains | $N/A |
| Jan 9, 2025 | Barclays | Matt Miksic | Overweight | Maintains | $26.00 |
| Oct 31, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Oct 21, 2024 | Alliance Global Partners | Buy | Initiates | $N/A |
InMode Ltd. (INMD) Competitors
The following stocks are similar to Inmode based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InMode Ltd. (INMD) Financial Data
InMode Ltd. has a market capitalization of $928.21M with a P/E ratio of 10.0x. The company generates $370.50M in trailing twelve-month revenue with a 25.3% profit margin.
Revenue growth is +6.1% quarter-over-quarter, while maintaining an operating margin of +25.0% and return on equity of +13.5%.
Valuation Metrics
Market Cap
$928.21M
Enterprise Value
$355.76M
P/E Ratio
10.0x
PEG Ratio
-0.2x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+6.1%
Gross Margin
+78.3%
Operating Margin
+25.0%
Net Margin
+25.3%
EPS Growth
-67.4%
Financial Health
Cash/Price Ratio
+61.2%
Current Ratio
9.9x
Debt/Equity
1.2x
ROE
+13.5%
ROA
+6.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
InMode Ltd. (INMD) Business Model
About InMode Ltd.
What They Do
Develops innovative medical aesthetic devices.
Business Model
The company designs and manufactures medical devices that utilize proprietary radiofrequency technology for aesthetic procedures. It generates revenue by selling these devices to healthcare professionals in various specialties, including plastic surgery and dermatology, across multiple international markets.
Additional Information
Founded in 2008 and headquartered in Yokneam, Israel, InMode Ltd. specializes in minimally invasive and non-invasive treatments, offering products for a wide range of applications including skin rejuvenation and women's health. Its global distribution network enhances its reach and market presence.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
660
CEO
Mr. Moshe Mizrahy
Country
Israel
IPO Year
2019
Website
www.inmodemd.comInMode Ltd. (INMD) Latest News & Analysis
Latest News
Quick Summary
InMode Ltd. will hold a conference call on May 6, 2026, at 8:30 a.m. Eastern Time.
Why It Matters
The conference call indicates upcoming financial disclosures or strategic updates from InMode Ltd., which can impact stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
InMode Ltd. (Nasdaq: INMD) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, featuring CEO Moshe Mizrahy and CFO Yair Malca.
Why It Matters
InMode Ltd.'s participation in a prominent healthcare conference highlights its market presence and potential for investor interest, which may influence stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
InMode Announces New Share Repurchase Program
1 month ago
Quick Summary
InMode Ltd. (Nasdaq: INMD) has approved a new share repurchase program for up to 10% of its total shares outstanding, equating to about 6.38 million shares.
Why It Matters
InMode's share repurchase program signals confidence in its financial health, potentially boosting share value and indicating strong future performance, attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
InMode Ltd. (INMD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
1 month ago
Quick Summary
InMode Ltd. (INMD) participated in the Barclays 28th Annual Global Healthcare Conference, sharing insights and updates relevant to investors and the healthcare sector.
Why It Matters
InMode Ltd.'s presentation at a major healthcare conference may signal growth prospects and strategic direction, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
InMode Ltd. (Nasdaq: INMD) will participate in the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, at 12:30 pm ET, featuring CFO Yair Malca. A live webcast will be available.
Why It Matters
InMode's participation in key investor conferences highlights its commitment to transparency and engagement, potentially influencing investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
InMode (INMD) Stock Slips As Board Ends Review
1 month ago
Quick Summary
InMode's board committee reviewed multiple transaction proposals but deemed them inadequate for the company and its shareholders, deciding to discontinue the process.
Why It Matters
InMode's decision to halt transaction discussions signals potential instability or lack of value in current bids, which could impact share prices and investor confidence.
Source: Benzinga
Market Sentiment:
Negative
Frequently Asked Questions About INMD Stock
What is InMode Ltd.'s (INMD) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, InMode Ltd. (INMD) has a median price target of $16.00. The highest price target is $21.00 and the lowest is $15.00.
Is INMD stock a good investment in 2026?
According to current analyst ratings, INMD has 1 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INMD stock?
Wall Street analysts predict INMD stock could reach $16.00 in the next 12 months. This represents a 11.7% increase from the current price of $14.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InMode Ltd.'s business model?
The company designs and manufactures medical devices that utilize proprietary radiofrequency technology for aesthetic procedures. It generates revenue by selling these devices to healthcare professionals in various specialties, including plastic surgery and dermatology, across multiple international markets.
What is the highest forecasted price for INMD InMode Ltd.?
The highest price target for INMD is $21.00 from Matt Miksic at Barclays, which represents a 46.5% increase from the current price of $14.33.
What is the lowest forecasted price for INMD InMode Ltd.?
The lowest price target for INMD is $15.00 from Caitlin Cronin at Canaccord Genuity, which represents a 4.7% increase from the current price of $14.33.
What is the overall INMD consensus from analysts for InMode Ltd.?
The overall analyst consensus for INMD is neutral. Out of 11 Wall Street analysts, 1 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are INMD stock price projections?
Stock price projections, including those for InMode Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 9:06 PM UTC